Please login to the form below

Not currently logged in
Email:
Password:

Lorbrena

This page shows the latest Lorbrena news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s Talzenna cleared for breast cancer in Europe

Pfizer’s Talzenna cleared for breast cancer in Europe

Talzenna is one of four new targeted therapies it is hoping will drive growth in cancer, along with Xalkori follow-up Lorbrena (lorlatinib) in second-line ALK-positive NSCLC, SMO inhibitor

Latest news

  • Pfizer poaches cancer R&D head Jeff Settleman from Calico Pfizer poaches cancer R&D head Jeff Settleman from Calico

    That includes Xalkori follow-up Lorbrena (lorlatinib) for ALK-positive non-small cell lung cancer (NSCLC), PARP inhibitor Talzenna (talazoparib) for breast cancer, Daurismo (glasdegib) for acute myeloid leukaemia, and Vizimpro

  • Pfizer gets EU nod for Tagrisso rival Vizimpro Pfizer gets EU nod for Tagrisso rival Vizimpro

    Last November, the drugmaker claimed FDA approval for Xalkori follow-up Lorbrena (lorlatinib) in second-line ALK-positive NSCLC and SMO inhibitor Daurismo (glasdegib) for acute myeloid leukaemia, while in October

  • Pfizer gets first FDA nod for hedgehog inhibitor in AML Pfizer gets first FDA nod for hedgehog inhibitor in AML

    For Pfizer, the Daurismo is the fourth new cancer approval in the last couple of months, coming just a few days after it got the go-ahead for Lorbrena (lorlatinib) for

  • Pfizer claims rapid FDA nod for Lorbrena Pfizer claims rapid FDA nod for Lorbrena

    The FDA has granted approval to Pfizer's next generation ALK inhibitor lung cancer treatment Lorbrena, which will help it defend its presence in the market. ... Lorbrena can also be used in patients who have seen disease progression on Roche’s Alecensa

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics